Two endothelin antagonists, ZD1611 (3-{4-[3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)-2-pyridyl]phenyl}-2,2-dimethylpropanoic acid) and ZD2574 (2-(4-isobutylphenyl)-N -(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide), selective for the ET A receptor and intended for use in pulmonary hypertension, were tested in Beagle dogs at various doses for periods of up to 4 weeks. These studies included in vivo telemetric hemodynamic assessment, full histopathological and ultrastructural pathological evaluation of coronary arteries. Both drugs produced arteritis in small-and medium-sized coronary arteries after single or multiple doses, some of which were at or below the ED50. The distribution of lesions was predominantly in extramural arteries over the atria and atrioventricular groove of the right side of the heart and consisted of epicardial hemorrhage and arteritis. Systemic arteritis was also present at a lower incidence than the coronary arteritis, was located at different sites and appeared inconsistently. Ultrastructural changes in coronary arteries suggested that damage was the result of mechanical factors. Although these patterns of vascular injury possessed features in common with those induced in dogs by high doses of vasodilating antihypertensive drugs and inotropic agents, they were atypical, as there was no left ventricular myocardial necrosis, papillary muscle damage, or subendocardial hemorrhage suggestive of ischaemia or excessive inotropism. Moreover, physiological monitoring showed no evidence of exaggerated systemic hypotension or reflex tachycardia at doses associated with vascular damage. Consequently, the changes might be the result of a localized pharmacological process such as intense, prolonged vasodilatation in unsupported arteries that are well endowed with endothelin receptors and particularly sensitive to endothelin antagonism. This paper is respectfully dedicated to the memory of Allen Macpherson. 263 0192-6233/03$3.00+$0.00 * p < 0.5 (Student's t-test). Statistically significant reductions were seen in systolic and diastolic blood pressures 1 and 1.5 hours postdosing with 20 mg ZD1611/kg.
INTRODUCTION
Endothelin (ET-1) is a peptide of 21 amino acids that is synthesised principally by the endothelium, displays potent vasoconstrictor activity, and acts on vascular smooth muscle (both in vivo and in vitro) initiating a sustained long-acting contraction of slow onset that is resistant to washout from isolated arteries and veins of experimental animals and human (3, 4, 6, 11) . It is a more potent vasoactive agonist than angiotensin II, vasopressin, or noradrenalin, potentiates the effects of catecholamines and angiotensin II and is an important element of the homeostatic control of vascular tone (26) . Intravenous administration of ET-1 results in decreased cardiac output and increased peripheral vascular resistance associated probably with one or more of the following effects: a direct cardiac effect resulting in decreased left ventricular function, an indirect mechanism via the systemic circulation that reduces venous return, or extreme coronary vasoconstriction (26) .
Despite some advances in therapy, congestive heart failure remains a major cause of mortality and morbidity. At the present time, estimates of 5-year survival of chronic heart failure (CHF) patients are about 50%: with 50% survival of Class IV CHF patients being 1 year (7) . Novel therapies to ameliorate the debilitating consequences of CHF and other hypertension-related diseases are sought. Circulating ET-1 is elevated in a number of cardiovascular diseases including pulmonary hypertension, atherosclerosis, and chronic heart failure. Animal models using endothelin antagonists have implicated ET-1 as an important factor in pulmonary hypertension, acute and chronic renal failure, ischaemic and hemorrhagic stroke, myocardial infarction, and diabetic nephropathy (17, 28) . Endothelin receptor antagonists are therefore expected to be of substantial benefit in the treatment of such diseases. The chronic hypoxia rat model has shown that endothelin antagonists are effective in reducing pulmonary artery pressure, reducing right ventricular hypertrophy and preventing pulmonary vascular remodelling. Furthermore, clinical studies using Bosentan (a mixed ET A and ET B receptor antagonist) have demonstrated hemodynamic benefit as lowered pulmonary vascular resistance in patients with CHF (12) .
We describe the coronary and systemic arteritis induced by the 2 endothelin receptor antagonists ZD1611 and ZD2574 (shown here) that were in pharmaceutical development for the treatment of pulmonary hypertension. The specific binding of ZD1611 and ZD2574 to the human ET A receptor over the ET B receptor (ET A /ET B binding ratio) was 1,210 and 430, respectively. The arteritis observed in dog studies targeted at assessing the safety of these molecules was a contributory factor in their withdrawal from development for this disease indication. 
Study Design
Studies of maximum tolerated dose (MTD) of up to 23 days, or standard toxicity studies of 1, 2, or 4 weeks' duration employing daily oral dosing were performed in both male and female dogs in order to assess the systemic toxicity of these compounds prior to possible administration to humans.
All animals were dosed orally with drug mixed with lactose excipient contained in gelatin capsules. Controls received the equivalent amount of lactose as given to drug-treated animals. All animals were examined regularly for atypical signs and body weight and food consumption monitored. The animals were given ophthalmological examinations, physiological parameters were recorded, and a variety of clinical chemical and hematological parameters measured.
In addition, a single study (coronary arteritis investigative study detailed below) was performed in order to assess the temporal development and pathogenesis of the coronary arteritis following administration of ZD1611. All studies were compliant with U.K. Home Office requirements.
Physiological Assessments
In studies of 2 or 4 weeks' duration, the ECG (limb leads) and arterial systolic and diastolic blood pressure (via a temporarily cannulated central artery of the ear pinna) were recorded from conscious dogs standing in a sling. The recordings were made prestudy, during the first few days and at the end of the studies-both before, and at times corresponding with expected maximal exposure. Baseline and control group median values in these studies were generally between 120 and 130 beats per minute for heart rate and 100 to 120 mm Hg and 60 to 70 mm Hg for systolic and diastolic blood pressure, respectively.
Necropsy and Histological Assessment
In studies of 4 weeks' duration, all animals were sacrificed by exsanguination under deep anesthesia induced by pen-tobarbitone sodium and subjected to a full necropsy, major organs weighed, tissues taken and processed for histological examination. In studies of shorter duration, less comprehensive tissue sampling was performed. Samples of the heart consisted of sections taken through the atrium, the atrioventricular groove and the ventricle from left and right sides, the papillary muscle and any abnormalities.
Tissues were routinely processed into paraffin wax and thin sections stained with hematoxylin and eosin or, in order to examine the integrity of the arterial internal elastic lamina, by Miller's or van Gieson elastic stains. Study details (doses and duration of exposure) in relation to individual compounds are given in Table 1 .
Coronary Arteritis Investigative Study
Two groups of 4 male dogs were given either a single oral dose of 200 mg ZD1611/kg and sacrificed 24 hours later on day 2 or, 4 daily doses and sacrificed on the fifth day. Two control male animals received capsules containing lactose only and were sacrificed 24 hours later. All animals were sacrificed by exsanguination under deep anesthesia induced by pentobarbitone sodium. The heart was removed and perfused with warm saline and, on showing pallor, saline perfusion was replaced with Karnovsky's fixative and maintained until the organ became firm to the touch. Lesion localisation was achieved by identification of sites of vascular leakage (hemorrhage). Tissue samples were processed for both light and transmission electron microscopy.
Telemetry Study
Given the shared features of right coronary arterial pathology following administration of an endothelin antagonist or a vasodilator, a telemetry study was performed in order to attempt differentiation between the systemic physiological changes due to the former compared with the latter.
Four beagle dogs were surgically implanted with thoracic subcutaneous electrocardiogram electrodes, a telemetry transducer (Data Sciences, St Paul, MN, USA) and an arterial catheter, via the femoral artery, into the abdominal aorta. Several weeks later, these dogs were orally dosed with placebo (lactose), followed by a rising dose schedule of single oral doses of ZD1611 at 7-day intervals. Arterial systolic and diastolic blood pressure, heart rate, abdominal aortic +dP/dt max and an electrocardiogram lead that approximated to lead II were recorded from 4 hours before each dose to approximately 24 hours after each dose, based on 20-second samples of telemetry data at 5 minute intervals. Group mean values in these studies after dosing with placebo were generally between 100 and 110 beats per minute for heart rate and 120 to 130 mm Hg and 70 to 80 mm Hg for systolic and diastolic blood pressure, respectively.
RESULTS
The nature of the lesions in animals administered either ZD1611 or ZD2574 was the same. Compound-related necropsy findings were seen in the heart in premature decedents and at study termination. In the heart, macroscopic observations at necropsy were seen in 20% of animals given endothelin antagonists and consisted of red discolouration only. This was most commonly observed in the right atrium, often close to and extending into adipose tissue overlying the atrio-ventricular groove and consisted of multiple foci or discrete areas of bright/dark red discolouration, the largest measuring 18 × 10 mm ( Figure 1 ). In one animal, the left atrium also displayed similar small focal areas of bright red discolouration and in another these changes were exhibited in the left atrium only. One animal showed multiple small red foci in adipose tissue adjacent to the base of the aorta. Several histopathological changes were observed in the heart namely, focal/multifocal acute or subacute arteritis of small/medium-sized extramural coronary arteries was frequently associated with right atrial epicardial hemorrhage (Figures 2 and 3 ). Myocardial necrosis or myocarditis was seen in the right atrial periarterial myocardium in a few instances only ( Figure 3 ). These lesions were found mainly but not exclusively on the right side, being present most frequently in the right atrium and right atrio-ventricular groove. With few exceptions, findings on the left side were present in animals showing right atrial or right atrio-ventricular groove lesions. The severity of lesions was, in general, dose-related. No papillary muscle necrosis was present in any of the animals given an endothelin antagonist and examined in these studies.
The nature of the arteritis varied considerably, but commonly consisted of medial necrosis with acute or subacute medial and/or adventitial inflammatory cell infiltration, some intimal proliferation and in some instances, adventitial fibrosis. Occasionally, the adventitial inflammatory cell infiltration that was normally acute/subacute (but sometimes consisted of a chronic inflammatory infiltrate in studies of 28 days' duration) extended into the adjacent epicardium and myocardium. Breaks in the internal elastic lamina were sometimes observed at sites of medial necrosis or intimal proliferation (Figure 4 ). Neovascularisation was common in the adventitia in these lesions but was seen more rarely in periarterial locations that showed no inflammatory cell infiltrate ( Figure 5 ). Occasionally, hemosiderin-laden macrophages were seen in periarterial tissue indicative of previous resolved hemorrhage at these sites. The highly localized nature of these arterial lesions was especially evident in longitudinal or oblique sections of coronary or systemic arteries.
Lesions similar to those seen in coronary arteries were observed in the following organs: spinal cord, thyroid gland, stomach, urinary bladder, ovary, lung, peribronchial tissue ( Figure 6 ), and ileum ( Figure 7) . The drug-induced systemic arteritis seen in these studies was of variable and unpredictable distribution and showed no dose-relationship. In general terms, its distribution was closely similar to that of the acute stages of spontaneous polyarteritis in dogs-Beagle Pain Syndrome (16) . The systemic lesions that were regarded as being drug-induced based on their acute or subacute nature and increased incidence in treated dogs, displayed medial fibrinoid necrosis and an inflammatory infiltrate that was of either acute or subacute nature and matched the appearance of coronary arteritis if that was also present in the animal. Arteritis that was not regarded as being drug-related, ie, spontaneous arteritis as described by Hartman (15) , presented a quite different appearance and was seen only in the right coronary artery in 1 animal in the investigative study ( Figure 8 ). The incidence and severity of both the coronary and systemic arteritis (but not of the spontaneous arteritis) observed in the studies reported are detailed in Table 1 .
Investigative Coronary Arteritis Study
Compound-related histopathological changes were found in the hearts of all dogs on days 2 and 5. Both the right and left sides of the heart exhibited lesions that were present in the same locations as described previously. The lesions were of 2 related types. The first was epicardial hemorrhage that was usually associated with acute or subacute inflammatory cell infiltration. The second consisted of arteritis, which was present predominantly in extramural arteries: in one instance only was a right atrial intramural vessel similarly affected. Epicardial hemorrhage and inflammatory cell infiltration were frequently associated with arteritis.
Day 2: In general terms, the light microscopic lesions seen on day 2 were almost exclusively acute and were graded as less severe (minimal/ mild) by comparison with those seen on day 5. Arteritis was characterised by minimal subintimal or medial haemorrhage with few acute inflammatory cells present within the arterial media ( Figure 9 ): in some instances these were also adherent to the intimal luminal surface. Medial smooth muscle cell necrosis was also seen in conjunction with these other changes in some instances. Occasionally, focal disruption of the internal elastic lamina was present with associated oedema of the subjacent media ( Figure 9 ).
By comparison with control vessels (Figure 10 ), ultrastructural evaluation of several arterial lesions from day 2 samples provided evidence of damage to the media and to the smooth muscle cells as illustrated by disruption of the basal laminae and of the intercellular space (to greater or lesser degrees) and the presence of lucent or dense cytoplasmic inclusions such as, large vacuoles, lipid droplets, myelinosomes, and autophagosomes ( Figure 11 ). Only a few necrotic smooth muscle cells were noted, and in one instance (in which no associated hemorrhage or inflammatory cell infiltration was present), adjacent smooth muscle cells appeared to be degenerating as illustrated by their irregular profiles, basal laminal disruption, plasmalemmal and attachment plaque contraction, and accumulation of cytoplasmic inclusion bodies. In other day 2 samples, intramedial erythrocytes and inflammatory cells were located within the smooth muscle cell basal laminae ( Figure 11 ). Smooth muscle cell necrotic debris was seen in conjunction with viable or necrotic inflammatory cells, erythrocytolysis, fragmentation and occasionally fibrin deposits (Figure 12a or b). Disruption (or separation of the elements) of the internal elastic lamina was also observed occasionally. Substantial disruption of the intima was also seen, as indicated by the presence of interendothelial gaps, inflammatory cell intimal attachment, trans-intimal inflammatory cell migration and insinuation between the endothelium and the subjacent internal elastic lamina (Figure 12a or b) .
Day 5: The lesions in day 5 animals were generally more severe than those seen on day 2. More inflammatory cell infiltrates associated with epicardial hemorrhage or arteritis were of a subacute nature although several were acute. Arteriolar medial hemorrhage was observed in the right atrioventricular groove of one animal in which epicardial acute inflammatory cell infiltration was also seen. Miller's stain demonstrated The ultrastructural appearances of tissue from day 5 animals were more significantly altered by comparison with those at day 2 and displayed additional features. Some smooth muscle cells showed unusually abundant cytoplasmic glycogen deposits, microvacuolation or swollen mitochondria that did not appear to be of artefactual cause. Smooth muscle plasmalemmal separation from the basal lamina by intercalation of erythrocytes and inflammatory cells was a common feature at this time. Medial hemorrhage, erythrocytolysis (or fragmentation) and/or trapped plasma were located both inside and outside smooth muscle cell basal laminae. The abundant medial and adventitial necrotic debris and in some cases fibrin, present at this time had been and was being phagocytosed by macrophages. Intimal endothelial cell necrosis with associated repair (rounded endothelial cell forms) was observed occasionally (Figures 12a or b and 13) . Subendothelial trapping of plasma, erythrocytes, or inflammatory cells (principally neutrophils) was present more commonly than on day 2.
Severe focal chronic arteritis seen in one day 2 animal was characterised by medial necrosis, intimal proliferation and periarterial chronic inflammatory cell infiltration (with lymphoid centres) in the right circumflex artery in the atrioventricular groove (Figure 8 ). The nature of the change confirms its previous development placing it into the context of a spontaneous chronic arteritis that is seen occasionally in this Beagle dog colony at a low incidence of less than 2% of all untreated animals (15) .
Physiological Assessments
ZD1611: In a 4-week oral toxicity study, blood pressure was reduced by approximately 25% throughout the dosing period at 200 mg/kg/day only and was accompanied during the first few days only by a small (approximately 15%) increase in heart rate ( Table 2 ). In the telemetry study, a dose of 20 mg/kg reduced blood pressure by up to 20% between 1 and 2 hours after dosing but did not alter heart rate (Table 3) .
ZD2574: No changes were detected in a 14-day oral toxicity study at doses up to 75 mg/kg/day. A telemetry study was not performed.
DISCUSSION
Oral administration of ZD1611 or ZD2574 to dogs for 1 to 30 days generated focal or multifocal arteritis and associated hemorrhage in small and medium-sized coronary arteries, predominantly in the right atrium and right atrioventricular groove. Similar lesions were present following daily dosing of 0.2 mg ZD1611/kg/day for 1 month. An important finding of the investigative study was that of the pres- Whereas drugs may induce vascular damage through a number of mechanisms, including direct cytotoxicity, thrombosis or thromboembolism and immune-mediated reactions, many cardioactive drugs seem able to produce coronary arteritis in the dog through exaggerated or sustained effects on vasomotor tone, usually through excessive vasodilatation but also by intense vasoconstriction (14) . Canine coronary arteritis has been observed following the oral or intravenous administration of a number of different pharmacologically active drugs that include sympathomimetic amines, theobromine, minoxidil, calcium channel blockers, an adenosine agonist anti-hypertensive and inotropic phosphodiesterase inhibitors (5, 9, 10, 13, 18, 19, 22, 23, 25, 27) . Despite the diversity of these agents, many possess a common capacity at high doses to induce vasodilatation with associated severe hypotension and reflex tachycardia. This leads to excessive arterial wall tension that damages the arterial wall, particularly in predisposed vascular beds such as the coronary arteries that are unsupported by surrounding parenchyma. In these cases the presence of arteritis is typically accompanied by myocardial ischaemia due to a combination of low arterial pressure, reduced diastolic perfusion time and increased cardiac oxygen demand, which in some cases is potentiated by inotropic activity. Mesfin et al (24) noted that these effects were TOXICOLOGIC PATHOLOGY 130  142  124  124  134  Day 2 or 3, predose  130  138  132  138  152  Day 2 or 3, 4 hours postdose  124  142  122  140  150  Day 22 or 23, predose  124  124  118  108  120  Day 22 # p < 0.5 (Jonckheere-Terpstra nonparametric trend test). Measurements were recorded prestudy, on days 2 or 3 and on days 22 or 23 predose and 4 hours postdose. These data indicate that a modest statistically significant reduction in systolic blood pressure occurs 4 hours postdose only in animals given 200 mg ZD1611/kg/day on day 22/23 of the study. associated with significant and measurable systemic hemodynamic alterations, typically a combination of heart rate increases of over 50 beats per minute above resting heart rate and mean arterial blood pressure decreases of at least 30 mm Hg.
The morphological appearances of the lesions produced by endothelin antagonists in this study are compatible with mechanical damage rather than cytotoxicity, but marked and sustained cardiovascular physiological changes of hypotension and tachycardia, and myocardial pathology, typical of vasodilator-induced changes were not observed as is amply illustrated in Table 2 . Indeed, ZD1611 only reduced blood pressure in dogs at doses well in excess of those that produced arterial lesions and this was accompanied by little or no increase in heart rate. This indicates that generalised systemic vasodilatation is unlikely to be a significant factor in the aetiology of endothelin antagonist-induced arterial lesions in dogs. Possible explanations for the reductions in blood pres- sure include reduced stroke volume due to mild venodilatation, or reduced arterial input impedance due to increased arterial compliance.
Clues to the pathogenesis of the initial lesions in endothelin antagonist-induced coronary arteritis include isolated observations of focal medial smooth muscle cell necrosis or disruption of the internal elastic lamina with associated subjacent medial oedema. Medial smooth muscle cell necrosis was associated with disorganisation or disruption of their basal laminae and those of adjacent cells that also displayed various lucent and dense cytoplasmic inclusions and separation of plasmalemmae from their basal laminae. The observed colocalisation of focal internal elastic lamina damage and medial injury is indicative of a mechanical basis for injury as has been observed following exposure to other vasoactive drugs and implicated as a primary factor in lesion pathogenesis (20, 25) . Disruption or breaks in the internal elastic lamina were observed in several of our studies. The medial hemorrhage, further smooth muscle cell necrosis and inflammatory cell infiltration and the observed degenerative and reparative changes of the intimal endothelium probably follow sustained arterial wall distension. The ultrastructural features of the prenecrotic, smooth muscle cell degeneration observed in this study are the same as those observed following intoxication of cells by xenobiotics or by intense vasodilatation due to vasoactive molecules (for references see 19) . Ultrastructural evidence of contraction of a few subintimal smooth muscle cells is indicative of loss of their plasmalemmal attachments. While endothelin antagonists administered parenterally or orally induce coronary arterial damage within 24 hours of administration (2, 21) . Albassam et al have demonstrated complete resolution of arteriopathy within 29 days of cessation of treatment.
No evidence of direct arterial toxicity has been demonstrated, and it is probable that the lesions develop as a result of the pharmacological action of endothelin antagonists. Endothelin is an important modulator of arterial tone acting through ET A and a subtype of ET B receptors on smooth muscle cells of the arterial media to promote vasoconstriction (20) . Specific ET A receptor antagonism may counter the ET-1 induced smooth muscle cell contraction associated with agonism of a subtype of the ET B receptor located on medial Vol. 31, No. 3, 2003 ENDOTHELIN ANTAGONIST-INDUCED ARTERITIS 271 smooth muscle cells, leading to focal dilatation of the flaccid vessel wall, and result in reduced arterial tone that, in unsupported coronary arteries, may lead to focal or multifocal damage. In a substantial contribution, Louden et al (20) reported that blockade of ET A and ET B receptors by the mixed ET-1 receptor antagonist SB209670 administered by intravenous infusion at a dose of 50 µg/kg/min for 5 days resulted in right atrial extramural coronary arteriopathy in conjunction with minor but sustained increases in heart rate (10-30 beats/min) and slight decreases in mean arterial blood pressure (10-15 mm Hg) that are similar to those due to the ZD compounds. The magnitude of these changes in systemic cardiovascular functional measures was much smaller than those that occur following administration of, for example, potassium channel openers. The possibility that more substantial blood pressure and flow changes may occur locally within the heart, and that these are responsible for the arterial lesions observed is supported by Louden et al (21) who reported a 6-fold increase in right atrial flow at 5 days of infusion with SB209670. Flow in other chambers was not significantly altered. In an assessment of endothelin receptor distribution in the heart, Louden and colleagues determined that the densities of ET A and ET B receptors were greatest in the vessels of the right atrium (by about 2×), of intermediate density in the left atrium and left and right atrial appendages and lowest in both ventricles and in the septum. The studies of Louden et al and ourselves concur that the distribution of the majority of lesions was in the right atrium (or right atrioventricular groove) with substantially fewer lesions in the left atrium. Noteworthy was their report of coronary artery endothelin receptor density being 5-6-fold greater than in atrial or ventricular regions. Furthermore, the distribution of endothelin receptor subtypes displayed substantial differences, namely that ET B receptors were present in vascular smooth muscle and predominated by 3-fold in right vs left coronary arteries. The density of ET A receptors in right and left coronary arteries was comparable. The notion that the pathogenesis of the lesions observed in the dog coronary vasculature is based upon differential densities of endothelin receptors and that it would perhaps result from extreme local arterial dilatation with associated substantial changes in local hemodynamics but potentially minor changes in systemic cardiovascular physiological parameters is attractive. If such a mechanism is plausible, the systemic arteritis of largely unsupported arteries seen in our studies might be expected to follow a similar pathogenesis. The available evidence that a mixed ET A /ET B receptor antagonist (SB209670) and ET A receptor antagonists (ZD1611 and ZD2574 with human ET A to ET B receptor binding specificities of 430 to >1,210) induce coronary arteritis with very similar characteristics encourages speculation that common effects arise via subtly different routes in a highly flexible and, at the present time, incompletely understood system of vascular control. However, no data on differential distribution of systemic arterial endothelin receptors is currently available. The induction of coronary arteritis by endothelin antagonists in species other than dog remains relatively little explored although the monkey has been shown to be sensitive (1) . It is noteworthy, that both dog and human coronary arteries possess high concentrations of endothelin receptors (8) . Indeed, these workers have demonstrated that all human cardiac vessels studied, namely, aorta (both normal and atheroscle-rotic), epicardial coronary artery and intramyocardial resistance vessels possess ET A receptors either, as a very high proportion (85-98%) or exclusively. Moreover, similar ET A receptor levels have been observed in major arteries and veins in lung, brain, kidney, and adrenal tissues. Separation of drug-induced arteritis from spontaneous arteritis in both coronary and systemic vessels is of substantial importance to toxicological pathologists. In relatively short duration studies in which coronary and systemic arteritis are of similar appearance with inflammatory cell infiltration of appropriate age with regard to time on study, a diagnosis of drug-induced pathogenesis is relatively straightforward and is distinguishable from spontaneous lesions of a more chronic inflammatory nature. In the studies reported here, such assessments were made on this basis. Greater difficulties are manifested in studies of longer duration, when resolving arterial damage with associated chronic inflammation more closely resembles chronic spontaneous arteritis. In this series of studies, the anatomical distribution (in systemic arteries) of the relatively low incidence of drug-induced systemic arteritis showed considerable overlap with that of spontaneous arteritis (Beagle Pain Syndrome). Our belief is that these lesions were drug-induced because the incidence significantly exceeded the frequency of the spontaneous disease seen in this Beagle dog colony. The pertinent question regarding their location in such coincidental sites implicates exacerbation of a pre-existent lesion or, an inherent susceptibility in vessel structure at that site. In the absence of sequential markers for arteritis or high resolution, in-life imaging tools, this cannot be resolved at present.
There is a growing awareness in the Regulatory community that dogs may be highly susceptible to the development of these lesions compared with humans. However, further assessments of the pathogenesis of canine coronary arteritis are required in order to substantiate this perception. Although the precise mechanism involved in the development of this coronary arteritis in the dog remains unclear, it is not associated with systemic vasodilatation, hypotension, and reflex tachycardia that are easy to monitor in patients. It is noteworthy in this regard that Bosentan, a nonselective ET A /ET B antagonist that induces canine coronary arteritis, has been administered to humans for more than 2,000 patient years without indications of adverse events relating to drug-induced arteritis (29) and has been licensed for the treatment of pulmonary hypertension.
